Bundang CHA Hospital

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.bundang.chamc.co.kr

Clinical Trials

Etiology of Motor Developmental Delay in Children

Completed

Conditions: Delayed; Development, Intellectual
Delayed;Development;Physical

First Posted Date: 2017-04-27

Last Posted Date: 2017-04-27

Lead Sponsor: Bundang CHA Hospital

Target Recruit Count: 1355

Registration Number: NCT03130972

Melatonin Study Between Diminished and Normal Responder in IVF

Not Applicable

Conditions: Infertility, Female

Interventions: Drug: Melatonin adminstration
Drug: placebo administration

First Posted Date: 2017-04-18

Last Posted Date: 2018-07-13

Lead Sponsor: Bundang CHA Hospital

Target Recruit Count: 100

Registration Number: NCT03117725

Locations: 🇰🇷
Bundang CHA medical center, Seongnam si, Gyeonggi Do, Korea, Republic of

Clinical Trial to Evaluate the Potential Efficacy and Safety of Human Umbilical Cord Blood and Plasma

Phase 1

Conditions: Aging

Interventions: Other: Frozen cord blood(experimental group B)
Other: Frozen plasma(experimental group C)
Other: Placebo group
Other: Fresh cord blood(experimental group A)

First Posted Date: 2015-04-16

Last Posted Date: 2016-01-13

Lead Sponsor: Bundang CHA Hospital

Target Recruit Count: 64

Registration Number: NCT02418013

Locations: 🇰🇷
Bundang CHA hospital, Seong nam, Bundanggu, Korea, Republic of

Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease

Phase 1

Conditions: Idiopathic Parkinson Disease
Primary Parkinsonism

Interventions: Drug: Mesencephalic Neuronal Precursor Cells

First Posted Date: 2013-05-23

Last Posted Date: 2020-07-10

Lead Sponsor: Bundang CHA Hospital

Target Recruit Count: 15

Registration Number: NCT01860794

Locations: 🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of

Erythropoietin Therapy for Children With Cerebral Palsy

Phase 2

Completed

Conditions: Cerebral Palsy

Interventions: Drug: Placebo erythropoietin
Drug: Erythropoietin

First Posted Date: 2012-07-26

Last Posted Date: 2017-10-12

Lead Sponsor: Bundang CHA Hospital

Target Recruit Count: 11

Registration Number: NCT01650415

Locations: 🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of

FLT-PET Activity Change After Allogeneic Umbilical Cord Blood (UCB) Therapy in Cerebral Palsy

Phase 2

Withdrawn

Conditions: Cerebral Palsy

Interventions: Biological: Umbilical Cord Blood Infusion
Other: Active Rehabilitation
Other: Placebo Umbilical Cord Blood

First Posted Date: 2011-12-06

Last Posted Date: 2013-11-19

Lead Sponsor: Bundang CHA Hospital

Registration Number: NCT01486732

Locations: 🇰🇷
CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of

Allogeneic Umbilical Cord Blood Therapy for Chronic TBI

Not Applicable

Withdrawn

Conditions: Traumatic Brain Injury

Interventions: Biological: Allogeneic Umbilical Cord Blood

First Posted Date: 2011-10-13

Last Posted Date: 2014-04-03

Lead Sponsor: Bundang CHA Hospital

Registration Number: NCT01451528

Locations: 🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of

Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD)

Phase 4

Completed

Conditions: Attention Deficit Hyperactivity Disorder

First Posted Date: 2009-02-12

Last Posted Date: 2009-02-12

Lead Sponsor: Bundang CHA Hospital

Target Recruit Count: 150

Registration Number: NCT00842127

Locations: 🇰🇷
Bundang CHA hospital, Seongnam, Kyonggi-do, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy